| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 First Department of Internal Medicine, Sapporo Medical University, Sapporo, and 2 Department of Clinical Laboratory Science, Yamaguchi University School of Medicine, Ube, Japan
Purpose: The aim of this study was to characterize the relationship of insulin-like growth factor (IGF)-II expression with IGF-I, IGF-I receptor (IGF-IR), cyclooxygenase-2 (COX-2), and matrix metalloproteinase (MMP)-7 in early colorectal carcinogenesis.
Experimental Design: With the semiquantitative reverse transcriptase-PCR, 90 human colorectal tumor tissues (63 adenomas and 27 submucosal pT1 cancers) were analyzed for IGF-II, IGF-IR, IGF-I, COX-2, and MMP-7 expression. Ninety-nine adenoma tissues and 60 pT1 cancer tissues were also analyzed immunohistochemically for IGF-II expression. Loss of imprinting of the IGF-II gene was analyzed. Paired carcinoma and adenoma tissues obtained from a carcinoma in adenoma lesion was analyzed by a cDNA array.
Results: IGF-II mRNA expression was detected in 37.8% of the 90 colorectal tumor tissues. The frequency of IGF-II mRNA expression was significantly higher in pT1 cancer (70.4%) than in adenoma (23.8%). Immunohistochemical IGF-II expression was also more frequently detected in pT1 cancer (58.3%) than in adenoma (25.3%). Loss of imprinting of the IGF-II gene was observed in 15 (44.1%) of the 34 colorectal tumors in which IGF-II was overexpressed. IGF-II expression was positively correlated with the expression of IGF-IR and IGF-I. COX-2 and MMP-7 mRNA expression was detected in 42.2% and 77.8% of the tumor tissues, respectively, and both were positively correlated with IGF-I, IGF-II, and IGF-IR expression. IGF-II was the most differentially expressed gene between carcinoma and adenoma lesions.
Conclusions: IGF-II, in conjunction with IGF-IR, IGF-I, COX-2, and MMP-7, seems to play a key role in the early stage of colorectal carcinogenesis.
This article has been cited by other articles:
|
|
 |
|
  J. R. Hecht Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S15 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Harper, J. L. Burns, E. J. Foulstone, M. Pignatelli, S. Zaina, and A. B. Hassan Soluble IGF2 Receptor Rescues ApcMin/+ Intestinal Adenoma Progression Induced by Igf2 Loss of Imprinting Cancer Res., February 15, 2006; 66(4): 1940 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Kornprat, P Rehak, J Ruschoff, and C Langner Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours J. Clin. Pathol., February 1, 2006; 59(2): 202 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Nosho, H Yamamoto, M Mikami, T Takahashi, Y Adachi, T Endo, K Hirata, K Imai, and Y Shinomura Laterally spreading tumour in which interstitial deletion of {beta}-catenin exon 3 was detected Gut, October 1, 2005; 54(10): 1504 - 1505. [Full Text] [PDF]
|
|
|
|
|
|
E. Hemers, C. Duval, C. McCaig, M. Handley, G. J. Dockray, and A. Varro Insulin-Like Growth Factor Binding Protein-5 Is a Target of Matrix Metalloproteinase-7: Implications for Epithelial-Mesenchymal Signaling Cancer Res., August 15, 2005; 65(16): 7363 - 7369. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
